Redeye: Genovis Q2 2025 - Undramatic report but recent developments are case supporting
13 augusti, 11:47
13 augusti, 11:47
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimates and the recently expanded licese agreement with Thermo Fischer which we find supportive to the long-term case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Genovis Q2 2025 - Undramatic report but recent developments are case supporting
13 augusti, 11:47
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimates and the recently expanded licese agreement with Thermo Fischer which we find supportive to the long-term case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Genovis Q2 2025 - Undramatic report but recent developments are case supporting
Aktieanalyser
Börsen
New Wave
Rapporter
Aktieanalyser
Börsen
New Wave
Rapporter
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 640,70